Ultra-low Temperature Transportation Will Facilitate the Growing Cell & Gene Market
RESEARCH TRIANGLE PARK, N.C., May 15, 2018 /PRNewswire/ -- Marken today announced the expansion of its cryogenic (liquid nitrogen) service locations to facilitate global cell & gene therapy trials. Marken's expanded network now includes facilities in Philadelphia, New York, Los Angeles, Miami, London, Frankfurt, Singapore and Tokyo. Johannesburgwill be added later this year to complete the global network. The combination of its expanded locations and packaging fleet allows Marken to meet client demands in a rapidly growing industry.
The global gene therapy market is projected to grow to $363m by 2022. An estimated 2,200 clinical trials are expected to drive this growth and will focus on oncology, rare diseases, Parkinson's, HIV, severe combined immuno-deficiencies (SCID) and hemophilia. The majority of these trials are projected to take place in the US, Europe, Canada and China1.
Wes Wheeler, Marken's Chief Executive Officer, commented, "We continue to see an increase in the demand for cell and gene therapy trial shipments. We are committed to building the largest cryogenic service network in the clinical logistics industry in order to serve our clients who are engaged in immunotherapy research."
1 Global Gene Therapy Market Analysis & Forecast to 2022, Kelly Scientific Publications, March 2018